Highlights from the virtual conference To view this email as a web page,
click here Bristol Myers' Opdivo one-ups Merck's Keytruda with presurgery lung cancer win Zentalis' WEE1 inhibitor shows promise in phase 1, with potential for combos down the line BeiGene details Novartis-partnered PD-1's first global pivotal win in lung cancer. Should Opdivo maker BMS be concerned? Sanofi's engineered IL-2 clears safety hurdles in early phase 1 data A 'tissue agnostic' indication for Retevmo? Lilly says it's possible with RET cancer win Bayer's Aliqopa, in redemption of the PI3K drug class, leaps ahead of Gilead's Zydelig in lymphoma OncoMyx's engineered rabbit pox virus shows promise in lung cancer model MD Anderson team uncovers new target for blocking mutant KRAS and p53 in pancreatic cancer Featured Story | By Angus Liu Bristol Myers Squibb’s Opdivo may be less popular than Merck & Co.’s Keytruda in metastatic non-small cell lung cancer, but it has just notched an important clinical win for earlier presurgery use among patients with early-stage disease that its archrival can’t yet tout. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus PARP inhibitors such as Merck and AstraZeneca’s Lynparza have changed the game for patients with ovarian cancer, but they’re still not a cure, as cancers can outsmart these drugs and develop resistance. Zentalis Pharmaceuticals is developing a WEE1 inhibitor that it hopes to combine with PARP inhibitors and other cancer medicines to boost their efficacy—and its early phase 1 data are promising. read more By Angus Liu BeiGene has detailed its Novartis-partnered tislelizumab's first global pivotal trial win, teeing up a potential filing outside its home country. The PD-1 drug cut the risk of death by 36% over docetaxel in previously treated non-small cell lung cancer. read more By Amirah Al Idrus Sanofi bet big on engineered IL-2 in 2019, dropping $2.5 billion to acquire Synthorx and its lead program, THOR-707. Now, the French pharma is reporting early phase 1 data showing the treatment could deliver the promise of cytokines for cancer treatment without their nasty side effects. read more By Angus Liu Eli Lilly’s Retevmo is already approved to treat lung and thyroid cancers driven by alterations in the RET gene. Now, the Indianapolis pharma believes it has data to support an expansion into all cancers bearing that biomarker. read more By Angus Liu PI3K inhibitors were once viewed as a blockbuster opportunity in blood cancer. But patient deaths in clinical trials for earlier-line use of Gilead Sciences’ first-to-market Zydelig dashed those hopes. Now, in what could be viewed as a redemption of the drug class, Bayer’s Aliqopa has safely come up with a success. read more By Angus Liu OncoMyx Therapeutics showed its armed rabbit pox virus could stimulate several inflammatory pathways relevant to an anti-tumor immune response. The therapy slowed tumor growth in a mouse model of non-small cell lung cancer. read more By Arlene Weintraub An MD Anderson team discovered that mutant KRAS and p53 rely on a protein called CREB1 to drive the growth and spread of pancreatic cancer. Blocking CREB1 in mouse models of the disease reduced metastases, they reported. read more |
|
